Search Result

Results for "

PET radioligand

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amyloid-β (2) Biochemical Assay Reagents (4) Cannabinoid Receptor (3) GlyT (1) GSK-3 (1) Histamine Receptor (2) LPL Receptor (1) LRRK2 (1) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (1) Sigma Receptor (2) Synaptic Vesicle Proteins (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (12)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113938

AZD4694 NAV4694	Amyloid-β	Cardiovascular Disease
AZD4694 (NAV4694), a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for Aβ fibrils (K_d = 2.3 nM) .

HY-141804

ER176	Biochemical Assay Reagents	Neurological Disease
ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

HY-136873

UCB-J	Synaptic Vesicle Proteins	Others
UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .

HY-155741

*CB2 PET* Radioligand 1**	Cannabinoid Receptor	Neurological Disease
CB2 PET Radioligand 1 (compound [18F]9) is a PET Radioligand targeting to hCB2 (Ki=7.7 nM). CB2 PET Radioligand 1 is prepared with Cu-mediated 18F-fluorination. CB2 PET Radioligand 1 shows high brain uptake in a murine model of neuroinflammation .

HY-174923

AZ12943203	Biochemical Assay Reagents GSK-3	Neurological Disease
AZ12943203 (Compound 13e) is a GSK-3 PET radioligand with a K_d of 2.94  nM. AZ12943203 has a significant inhibitory potency toward GSK-3β (IC₅₀: 4.44 nM), and can specifically bind to GSK-3-rich regions of the rodent brain. AZ12943203 can be used for neurodegenerative diseases imaging, particularly Alzheimer’s disease .

HY-167898

MeS-IMPY	Amyloid-β	Neurological Disease
MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (K_i=7.93 and 8.95 nM, respectively). [ ¹¹C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET) .

HY-175367

H3R antagonist 6	Histamine Receptor Sigma Receptor	Neurological Disease
H3R antagonist 6 (Compounds 3) (H3-2406) is a Histamine receptor 3 (H3R) antagonist with an IC₅₀ of 5.6 nM. H3R antagonist 6 labeled with 18F has high radiochemical yield, molar activity and moderate brain uptake, but with an off-target binding to the Sigma-1 receptor. H3R antagonist 6 can be used as a PET radioligand for positron emission tomography imaging for central nervous system (CNS) disorders research .

HY-171806

BMT-136088	LPL Receptor	Cancer
BMT-136088 is a radioligand used for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis .

HY-156124

*Sigma-2 Radioligand* 1**	Sigma Receptor	Cancer
Sigma-2 Radioligand 1 (compound 1) is a Sigma-2 selective ligand. Sigma-2 Radioligand 1 has good biodistribution in mice and good in vivo activity in rats. [18F] Modified Sigma-2 Radioligand 1 for visualization of tumors in micro-PET/CT imaging, exhibiting high tumor uptake and tumor-to-background ratio. Experiments show that Sigma-2 Radioligand 1 binds highly specifically in U87MG glioma xenografts .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Others
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-103326

NIDA-41020	Cannabinoid Receptor	Neurological Disease
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .

HY-149869

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

HY-175372

H3R antagonist 7	Histamine Receptor	Neurological Disease
H3R antagonist 7 (compounds 4) is a histamine subtype 3 receptor (H3R) antagonist with a K_i of 3.15 nM. H3R antagonist 7 is a potential PET radioligand for the study of central nervous system (CNS) diseases .

HY-D2343

PB0822	Biochemical Assay Reagents	Neurological Disease
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-161246

uPSEM792	5-HT Receptor	Neurological Disease
uPSEM792 is a pharmacologically selective effector molecules (PSEM) agonist for PSAM ⁴-GlyR, with an affinity of K_i of 0.7 nM. uPSEM792 is a substrate for efflux transporters in brains of wild type and dual P-gp and BCRP knockout mice. uPSEM7952 is a possible lead for developing the PET radioligand for PSAM ⁴-GlyR .

HY-111189

GSK931145	GlyT	Neurological Disease
GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .

HY-12761

A-836339	Cannabinoid Receptor	Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H₂O₂). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc .

Cat. No.	Product Name	Type

HY-D2343

PB0822	Dyes
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

Cat. No.	Product Name	Target	Research Area

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Others
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.